Abstract
While extremely prevalent, painful, and difficult to treat, vulvovaginal candidiasis remains largely understudied in the field of women's health. In a recent issue of mSystems, McKloud et al. (E. McKloud, C. Delaney, L. Sherry, R. Kean, et al., mSystems 6:e00622-21, 2021, https://doi.org/10.1128/mSystems.00622-21) shed light on a pivotal role of a complex Candida-Lactobacillus interplay that may regulate the pathophysiology of recurrent vulvovaginal candidiasis (RVVC). This advancement not only gives new insight into the molecular mechanisms governing interkingdom interactions modulating RVVC disease, but also provides evidence that probiotic Lactobacillus-based therapeutic approaches could be efficient for fighting these problematical fungal infections.